Hep C treatment recommended by NICE

The National Institute for Health and Care Excellence (NICE) has recommended Maviret (glecaprevir + pibrentasvir) from AbbVie for adults with chronic hepatitis C, suitable for all genotypes, with or without scarring of the liver (cirrhosis ) and in patients untreated or who have been treated before with interferon therapy.

Comment: Maviret is a once-daily regimen that combines two distinct antiviral agents - the NS3/4A protease inhibitor glecaprevir (300mg) and NS5A inhibitor pibrentasvir (120mg) - dosed once-daily as three oral tablets and shown in trials to cure the virus in just eight weeks. Regulators are allowing its use to treat patients without cirrhosis and who are new to treatment, who comprise the majority of the 71 million people living with chronic hepatitis C virus (HCV) infection globally, as well as those with specific treatment challenges, including those with compensated cirrhosis, severe chronic kidney disease or genotype 3 HCV.